¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Bone Morphogenetic Protein Receptors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • cantilever bone graft
    µé¸²»ÀÀ̽Ä
  • capitate bone
    ¾Ë¸Ó¸®»À
  • collar bone
    ºøÀå»À, ¼â°ñ
  • compact bone
    Ä¡¹Ð»À
  • cortical bone
    °ÑÁú»À, ÇÇÁú°ñ
  • costal bone
    °¥ºñ»À, ´Á°ñ
  • cranial bone
    ¸Ó¸®»À, µÎ°³°ñ
  • cranial bone flap
    ¸Ó¸®»ÀÇÇÆÇ(¼ú), µÎ°³°ñÇÇÆÇ
  • cuboid bone
    ÀÔ¹æ»À
  • cuneiform bone
    ½û±â»À, ¼³»ó°ñ
  • carpal bone
    ¼Õ¸ñ»À, ¼ö±Ù°ñ
  • cartilage bone
    ¿¬°ñ»À
  • cancellous bone
    °¹¼Ø»À, ÇØ¸é°ñ
  • endochondral bone
    ¿¬°ñ³»»À
  • ethmoid bone
    ¹úÁý»À, »ç°ñ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • compact bone
    Ä¡¹Ð»À
  • cortical bone
    °ÑÁú»À
  • costal bone
    (¢¡rib) °¥ºñ»À, ´Á°ñ
  • cranial bone
    ¸Ó¸®»À, µÎ°³°ñ
  • cuboid bone
    ÀÔ¹æ»À
  • cuneiform bone
    ½û±â»À
  • ethmoid bone
    ¹úÁý»À, »ç°ñ
  • flat bone
    ³³ÀÛ»À
  • frontal bone
    À̸¶»À
  • hamate bone
    °¥°í¸®»À
  • hammer bone
    (¢¡malleus) ¸ÁÄ¡»À
  • heel bone
    (¢¡calcaneus) ¹ß²ÞÄ¡»À
  • hip bone
    º¼±â»À, °ü°ñ
  • hyoid bone
    ¸ñ»Ô»À
  • innominate bone
    (¢¡hip bone) º¼±â»À, °ü°ñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • PPD (purified protein derivatives)
    ÇÇÇǵð, Á¤Á¦´Ü¹éÁú·ù(À¯µµÃ¼)
  • PPD(Purified protein derivative) test
    PPD °Ë»ç.
  • Reiters protein
    ¶óÀÌÅÍ ¸Åµ¶Áø´Ü¿ë´Ü¹éÁú
  • S100 protein
    S100 ´Ü¹éÁú
  • actin-binding protein
    ¾×ƾ °áÇմܹé(¡­Ì¿ùêÓ±ÛÜ)
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • activated protein C resistance
    Ȱ¼ºÈ­C´Ü¹é³»¼º
  • acute phase protein
    ±Þ¼ºº´±â´Ü¹éÁú
  • acute phase reactive protein
    ±Þ¼º±â ¹ÝÀÀ¼º ´Ü¹é.
  • amyloid precurssor protein
    ¾Æ¹Ð·ÎÀ̵å Àü±¸ ´Ü¹éÁú
  • androgen- binding protein
    ¸¸¼ºÈ£¸£¸ó °áÇմܹé
  • anion exchange protein
    À½À̿ ±³È¯ ´Ü¹é(ÎßüµÓ±ÛÜ)
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú(ù÷ÔÐÌ¿ Ó±ÛÜòõ).
  • ganglioside activator protein
    °»±Û¸®¿À»çÀ̵å Ȱ¼º´Ü¹éÁú
  • glial fibrillary acidic protein
    ½Å°æ±³¿ø¼¶À¯(Îïê«àéë«)»ê(ß«)´Ü¹é
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • penicillin binding protein (PBP)
    Æä´Ï½Ç¸° °áÇմܹéÁú
  • periplasmic binding protein
    ¿øÇüÁú¸· ÁÖÀ§°ø°£ °áÇմܹéÁú
  • perturbation of protein
    ´Ü¹éÁúº¯ÅÂ(Ó±ÛÜòõ ܨ÷¾).
  • pilus protein antigen
    ¼¶¸ð´Ü¹éÁúÇ׿ø
  • plasma protein
    Ç÷Àå´Ü¹é(Áú)
  • plasma protein
    Ç÷Àå´Ü¹éÁú(úìíìÓ±ÛÜòõ).
  • plasma protein binding
    Ç÷Àå´Ü¹é°áÇÕ.
  • plasma protein fraction =PCC
    Ç÷Àå´Ü¹éºÐȹ
  • principal outer membrane protein (POMP)
    ÁÖ¿ä¿Ü¸·´Ü¹éÁú
  • prosthetic protein
    ¹èÇÕ¼º ´Ü¹é(ÛÕùêàõÓ±ÛÜ).
  • protein
    ´Ü¹éÁú
  • protein
    ´Ü¹é(Ó±ÛÜ), ´Ü¹éÁú(Ó±ÛÜòõ)
  • protein
    ´Ü¹é(Áú)
  • protein 3
    ´Ü¹é 3
  • protein 4.1
    ´Ü¹é 4.1
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • matrix protein
    ±âÁú´Ü¹éÁú(ѨòõÓ±ÛÜòõ)
  • maturation protein
    ¼º¼÷´Ü¹éÁú(à÷âÙÓ±ÛÜòõ)
  • melting protein
    À¶ÇشܹéÁú(ë×ú°Ó±ÛÜòõ)
  • minimum protein requirement
    ÃּҴܹéÁú¿ä±¸·®(õÌá³Ó±ÛÜòõé©Ï´Õá)
  • moderator protein
    Á¶Á¤ÀڴܹéÁú(ðàïÚí­Ó±ÛÜòõ)
  • modulator protein
    Á¤Á¶´Ü¹éÁú(ïÚðàÓ±ÛÜòõ)
  • Mo-Fe protein
    Mo-Fe ´Ü¹éÁú(Ó±ÛÜòõ)
  • molybdoiron protein
    ¸ô¸®ºêµµÃ¶(ôÑ) ´Ü¹éÁú(Ó±ÛÜòõ)
  • M-protein
    M ´Ü¹éÁú(Ó±ÛÜòõ)
  • multifunctional protein
    ´Ù±â´É´Ü¹éÁú(ÒýÐüÒöÓ±ÛÜòõ)
  • multiheaded protein
    ´ÙµÎ´Ü¹éÁú(ÒýÔéÓ±ÛÜòõ)
  • mutant protein
    º¯À̴ܹéÁú(ܨì¶Ó±ÛÜòõ)
  • myelin basic protein
    ¼öÃÊ¿°±â¼º(âËÃÊç¤Ðñàõ) ´Ü¹éÁú(Ó±ÛÜòõ)
  • myelin protein A1
    ¼öÃʴܹéÁú(âËÃÊÓ±ÛÜòõ) A1
  • myeloma protein
    °ñ¼öÁ¾´Ü¹éÁú(ÍéâÐðþÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
BFR biologic false reaction; blood flow rate; bone formation rate; buffered Ringer [solution]
BG basal ganglion; basic gastrin; Bender Gestalt [test]; beta-galactosidase; beta-glucuronidase; bicolo...
BI background interval; bacterial or bactericidal index; base-in [prism]; basilar impression; Billroth ...
BIS bone cement implantation syndrome; Brain Information Service; building illness syndrome
BL Barre-Lieou [syndrome]; basal lamina; baseline; Bessey-Lowry [unit]; black light; bladder; bleeding;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
RACK Receptors for activated C kinase
SARs Slowly adapting pulmonary stretch receptors
SAR Slowly adapting receptors
SR Steroid receptors
TR T(3) receptors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bundle bone
    ¼Ó»ó°ñ
    Shar
  • calf's bone
    ºñ°ñ
    µ¿ÀǾî=fibula. ÇÏÅðÀÇ µÎ °³ÀÇ »À Áß¿¡¼­ ¹Ù±ùÂÊÀÇ ÀÛÀº °Í.
  • carpal bone
    ¼Õ¸ñ»À, ¼ö±Ù°ñ
  • cartilagenous bone
    ¿¬°ñ »À
    Ư¼öÇÑ ¼¶À¯¼º °áÇÕÁ¶Á÷ÀÇ »À. žÆÀÇ ÀϽÃÀû °ñ°ÝÀ» Çü¼ºÇÏ °í, °ñÀÌ ¹ß´ÞÇϱâ À§ÇÑ ÇüÀ» Á¦°øÇϸç, »ý¹° ¼ºÀå±â±¸ÀÇ Áß¿ä ºÎºÐÀ» ±¸¼ºÇÑ´Ù.
  • cartilaginous bone
    ¿¬°ñ¼º °ñ
  • cheek bone
    °ü°ñ
    µ¿ÀǾî=zygoma.
  • cheek malar bone
    ±Ç°ñ, °ü°ñ
  • coarse-fibered woven bone
    °ÅÄ£ ¼¶À¯¼º ±³Á÷°ñ
  • compact bone
    Ä¡¹Ð°ñ, Ä¡¹Ð»À
    µ¿ÀǾî=cortical bone. ´Ü´ÜÇϰí Ä¡¹ÐÇÑ Á¶Á÷ÀÌ¸ç °ñ ÇÇÁúÀ̶ó°íµµ ÇÑ´Ù. ÇØ¸é °ñ°ú °°Àº Á¶Á÷ÇÐÀû ±¸Á¶¸¦ °¡Áö³ª Ä¡¹Ð°ñÀÇ haversian systemÀÇ ¹è¿­ÀÌ Á»´õ ±ÔÄ¢ÀûÀÌ´Ù. Âü°í
  • condensed bone
    ³óÃà °ñºÎ
  • congenital and developmental bone disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º °ñ Àå¾Ö
  • developmental bone
    ¹ßÀ°¼º °ñ
  • diffuse atrophy of alveolar bone
    ¹Ì¸¸¼º Ä¡Á¶°ñ À§Ãà
  • endochondral bone growth
    ¿¬°ñ³» °ñ ¼ºÀå
  • facial bone
    ¾ó±¼ »À, ¾È¸é °ñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
receptors, leukocyte-adhesion Family of proteins associated with the capacity of leukocytes, including lymphocytes, monocytes, and neutrophils, to adhere to each other and to certain substrata, e.g., the c3bi component of complement. Members of this family are the lymphocyte function-associated antigen-1 (lfa-1), the macrophage-1 antigen (mac-1), and the antigen p150,95 or p150,95 leukocyte adhesion protein. They all share a common beta-subunit which is the CD18 antigen. All three of the above antigens are absent in inherited leukocyte-adhesion deficiency syndrome, which is characterised by recurrent bacterial infections, impaired pus formation, and wound healing as well as abnormalities in a wide spectrum of adherence-dependent functions of granulocytes, monocytes, and lymphoid cells.
(12 Dec 1998)
receptors, leukotriene Cell-surface receptors that bind leukotrienes with high affinity and trigger intracellular changes influencing the behaviour of cells. The leukotriene receptor subtypes have been tentatively named according to their affinities for the endogenous leukotrienes ltb4, ltc4, ltd4, and lte4.
(12 Dec 1998)
receptors, leukotriene b4 A class of cell surface leukotriene receptors with a preference for leukotriene b4. Leukotriene b4 receptor activation influences chemotaxis, chemokinesis, adherence, enzyme release, oxidative bursts, and degranulation in polymorphonuclear leukocytes. There are at least two subtypes of these receptors. Some actions are mediated through the inositol phosphate and diacylglycerol second messenger systems.
(12 Dec 1998)
receptors, lh Those protein complexes or molecular sites on the surfaces and cytoplasm of gonadal cells that bind luteinizing or chorionic gonadotropic hormones and thereby cause the gonadal cells to synthesise and secrete sex steroids. The hormone-receptor complex is internalised from the plasma membrane and initiates steroid synthesis.
(12 Dec 1998)
receptors, lhrh Receptors with a 6-kD protein on the surfaces of cells that secrete lh or fsh, usually in the adenohypophysis. Lhrh binds to these receptors, is endocytosed with the receptor and, in the cell, triggers the release of lh or fsh by the cell. These receptors are also found in rat gonads. Inhibin prevents the binding of gnrh to its receptors.
(12 Dec 1998)
receptors, lipoprotein Cell surface proteins that bind lipoproteins with high affinity. Lipoprotein receptors in the liver and peripheral tissues mediate the regulation of plasma and cellular cholesterol metabolism and concentration. The receptors generally recognise the apolipoproteins of the lipoprotein complex, and binding is often a trigger for endocytosis.
(12 Dec 1998)
receptors, lymphocyte homing Cell surface glycoproteins on lymphocytes and other leukocytes that mediate adhesion to specialised blood vessels called high endothelial venules. Several different classes of lymphocyte homing receptors have been identified, and they appear to target different surface molecules (addressins) on high endothelial venules in different tissues. The adhesion plays a crucial role in the trafficking of lymphocytes.
(12 Dec 1998)
receptors, macrophage colony-stimulating factor Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response.
(12 Dec 1998)
receptors, metabotropic glutamate Cell surface proteins that bind glutamate and act through g-proteins to influence second messenger systems. Several types of metabotropic glutamate receptors have been cloned. They differ in pharmacology, distribution, and mechanisms of action.
(12 Dec 1998)
receptors, mineralocorticoid Cytoplasmic proteins that specifically bind mineralocorticoids and mediate their cellular effects. The receptor with its bound ligand acts in the nucleus to induce transcription of specific segments of DNA. Mineralocorticoids were named for their actions on extracellular electrolyte concentrations. The most important example is aldosterone.
(12 Dec 1998)
receptors, mitogen Glycoprotein molecules on the surface of b- and T-lymphocytes, that react with molecules of antilymphocyte sera, lectins, and other agents which induce blast transformation of lymphocytes.
(12 Dec 1998)
receptors, muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for muscarine over nicotine. There are several subtypes (usually m1, m2, m3...) that are characterised by their cellular actions, pharmacology, and molecular biology.
(12 Dec 1998)
receptors, nerve growth factor Cell surface receptors that bind nerve growth factor (ngf) and trigger intracellular changes influencing the behaviour of cells. Nerve growth factor receptors mediate the effects of nerve growth factor on the survival and growth of neurons.
(12 Dec 1998)
receptors, neurokinin-1 A class of cell surface receptors for tachykinins with a preference for substance p. Neurokinin-1 (nk-1) receptors have been cloned and are members of the G-protein coupled receptor superfamily. They are found on many cell types including central and peripheral neurons, smooth muscle cells, acinar cells, endothelial cells, fibroblasts, and immune cells.
(12 Dec 1998)
receptors, neurokinin-2 A class of cell surface receptors for tachykinins that prefers neurokinin a (nka, substance k, neurokinin alpha, neuromedin l), neuropeptide k (npk), or neuropeptide gamma over other tachykinins. Neurokinin-2 (nk-2) receptors have been cloned and are similar to other g-protein coupled receptors.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á